Edition:
United States

Edwards Lifesciences Corp (EW)

EW on New York Consolidated

110.64USD
22 Sep 2017
Change (% chg)

$0.31 (+0.28%)
Prev Close
$110.33
Open
$110.48
Day's High
$110.84
Day's Low
$109.20
Volume
970,645
Avg. Vol
1,226,940
52-wk High
$121.75
52-wk Low
$81.12

Latest Key Developments (Source: Significant Developments)

Edwards Lifesciences Q2 shr $0.86 , Q2 adj shr $1.08
Wednesday, 26 Jul 2017 04:15pm EDT 

July 26 (Reuters) - Edwards Lifesciences Corp :Edwards lifesciences says 2017 adjusted eps guidance increased to $3.65 to $3.85, from $3.43 to $3.55.Edwards lifesciences corp q2 earnings per share $0.86; q2 adjusted earnings per share $1.08; q2 sales up 11 percent to $842 million; q2 underlying sales up 15 percent to $864 million.Edwards lifesciences q2 transcatheter heart valve therapy sales $487.5 million, a 16.5 percent growth rate over q2 last year, or 23.3 percent on an underlying basis.Edwards lifesciences says for fy 2017 sales estimate is now at high end of previous $3.2 billion to $3.4 billion guidance.Edwards lifesciences says for q3 projects underlying sales, adjusting for impact of germany stocking sales consumption, to be between $810 million and $850 million.Edwards lifesciences says projects q3 adjusted eps, adjusting for impact of germany stocking sales consumption, of $0.80 to $0.90.Q2 earnings per share view $0.88, revenue view $840.1 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $3.53, revenue view $3.35 billion -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.83, revenue view $824.7 million -- Thomson Reuters I/B/E/S.Edwards lifesciences says q2 reported, adjusted eps include $0.13 favorable impact from excess tax benefit related to employee stock-based compensation.  Full Article

Edwards' Inspiris Resilia valve receives FDA approval
Wednesday, 5 Jul 2017 09:00am EDT 

July 5 (Reuters) - Edwards Lifesciences Corp :Edwards' Inspiris Resilia valve receives FDA approval.Edwards Lifesciences Corp - Received U.S. FDA approval for its Inspiris Resilia aortic valve, first in a new class of resilient heart valves.  Full Article

Neovasc says German Court partially found in favor of Edwards Lifesciences in its case against co
Friday, 16 Jun 2017 10:44am EDT 

June 16 (Reuters) - Neovasc Inc ::Neovasc announces German Court ruling.District court in Munich has partially found in favour of Edwards Lifesciences Corporation in its case against Neovasc.German Court found CardiAQ had contributed in part to invention of Tiara, awarded to CardiAQ co-entitlement rights to disputed Tiara European patent application.Neovasc intends to appeal Court's decision.There are no monetary awards associated with the Court ruling.Currently appealing 2016 decision from U.S Court which granted co-inventorship rights to Edwards on one of co's granted U.S. patent applications.Expects oral argument on appeal regarding the 2016 decision by U.S. Court in August 2017 and ruling is expected to follow, prior to end of 2017.  Full Article

Edwards Lifesciences says SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures
Monday, 5 Jun 2017 04:30pm EDT 

June 5 (Reuters) - Edwards Lifesciences Corp :Edwards SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures.  Full Article

FDA expands use of Sapien 3 artificial heart valve for high-risk patients‍​
Monday, 5 Jun 2017 03:31pm EDT 

June 5 (Reuters) - U.S. Food and Drug Administration (FDA) : :FDA expands use of Sapien 3 artificial heart valve for high-risk patients‍​.U.S. FDA says granted accelerated approval of Sapien 3 THV to Edwards Lifesciences LLC.  Full Article

Edwards Lifesciences Q1 earnings per share $1.06
Tuesday, 25 Apr 2017 04:15pm EDT 

April 25 (Reuters) - Edwards Lifesciences Corp ::Says Q1 earnings per share $1.06; Q1 adjusted earnings per share $0.94; Q1 sales grew 27 percent to $884 million.Edwards Lifesciences Corp - narrowing its FY sales guidance to $3.2 billion to $3.4 billion, from $3.0 billion to $3.4 billion.Edwards Lifesciences Corp - raising estimate for 2017 adjusted earnings per share to $3.43 to $3.55, from $3.30 to $3.45.Edwards Lifesciences - sees Q2 sales, excluding impact of germany stocking sales, between $810 million and $850 million; sees Q2 adjusted earnings per share of $0.82 to $0.92.Edwards Lifesciences Corp - Q1 transcatheter heart valve therapy sales of $539.2 million, up 46.6 percent.Q1 earnings per share view $0.82, revenue view $776.4 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $3.41, revenue view $3.26 billion -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.87, revenue view $824.1 million -- Thomson Reuters I/B/E/S.  Full Article

German patent court issues initial decision
Thursday, 9 Mar 2017 06:35am EST 

Edwards Lifesciences Corp - : District court in Germany ruled that Boston Scientific's lotus valve infringes one of co's patents for transcatheter aortic valves . Edwards is not updating its 2017 financial guidance . Does not presently anticipate disruption to supply of sapien 3 valves to patients . Court also ruled Edwards Sapien 3 valve infringes two of Boston Scientific's patents for outer seals of transcatheter heart valves .Will promptly request an appeal.  Full Article

Boston Scientific receives favorable rulings in Edwards Lifesciences litigation
Thursday, 9 Mar 2017 04:59am EST 

Boston Scientific Corp : Boston scientific receives favorable rulings in edwards lifesciences litigation . German district court of Düsseldorf determined that Edwards Lifesciences infringed two patents of Boston Scientific . Edwards has stated that it will seek permission to appeal this judgment . Edwards Lifesciences and Boston Scientific can appeal each of four decisions as far as district court of Düsseldorf has decided against them .believes that '550 patent will be revoked by European patent office.  Full Article

Edwards Lifesciences says UK patent court issues decision on transcatheter heart valves
Friday, 3 Mar 2017 06:50am EST 

Edwards Lifesciences Corp : UK patent court issues initial decision . Edwards Lifesciences Corp says company is not changing its financial guidance . Edwards Lifesciences Corp - Edwards will promptly request an appeal on specific aspects of decision . Edwards Lifesciences-patents court in uk determined one of boston scientific's patents related to seals for transcatheter heart valves valve is invalid . Edwards Lifesciences Corp - court's decision does not affect commercial availability of sapien 3 valve . Edwards Lifesciences - boston scientific initiated litigation involves multiple patents in multiple venues, to yield court actions over extended period .Edwards Lifesciences Corp - patents court in uk has determined a second patent of Boston Scientific is valid and infringed.  Full Article

Edwards Lifesciences Corp Q4 EPS $0.73
Wednesday, 1 Feb 2017 04:15pm EST 

Edwards Lifesciences Corp : Q4 global transcatheter heart valve therapy sales up 29 percent to $432 million . Sees FY 2017 sales between $3.0 billion and $3.4 billion; Sees FY 2017 adjusted eps between $3.30 and $3.45 . Q4 EPS $0.73; Q4 adjusted EPS $0.75; q4 sales up 14 percent to $768 million . Sees Q1 2017 sales between $760 million and $800 million; Sees Q1 2017 adjusted EPS between $0.79 and $0.89 . Q4 earnings per share view $0.72, revenue view $759.5 million -- Thomson Reuters I/B/E/S . Fy2017 earnings per share view $3.39, revenue view $3.25 billion -- Thomson Reuters I/B/E/S .Q1 earnings per share view $0.81, revenue view $779.1 million -- Thomson Reuters I/B/E/S.  Full Article

Neovasc loses appeal of $112 million heart valve trade secrets award

A federal appeals court on Friday upheld an almost $112 million win for Edwards Lifesciences Corp, which accused rival medical device company Neovasc Inc of misappropriating its heart valve replacement technology.